A novel secreted tumor antigen with a glycosylphosphatidylinositol-anchored structure ubiquitously expressed in human cancers
Authors
Onda, H
Ohkubo, S
Shintani, Y
Ogi, K
Kikuchi, K
Tanaka, H
Yamamoto, K
Tsuji, I
Ishibashi, Y
Yamada, T
Kitada, C
Suzuki, N
Sawada, H
Nishimura, O
Fujino, M
Citation
H. Onda et al., A novel secreted tumor antigen with a glycosylphosphatidylinositol-anchored structure ubiquitously expressed in human cancers, BIOC BIOP R, 285(2), 2001, pp. 235-243
Categorie Soggetti
Biochemistry & Biophysics
Journal title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
SICI code
0006-291X(20010713)285:2<235:ANSTAW>2.0.ZU;2-7
Abstract
In a search for novel genes expressed in human cancers, we identified one g
ene from an assembled expressed sequence tag database. Northern blot analys
is revealed that the gene, termed alcan, was expressed in various types of
human cancer cell lines and in the fetus, but not in normal tissues. The al
can gene is located on chromosome 6 and is encoded on a 246-amino-acid prot
ein with weak homology to classical major histocompatibility complex class
I. Its gene product, ALCAN, had hydrophobic amino acid clusters at both the
N- and C-terminal regions and was predicted to be a glycosylphosphatidylin
ositol (GPI)anchored membrane protein. Flow cytometric analysis revealed th
at ALCAN was detected on the surface of human cancer cells and on alcan-tra
nsfected CHO-K1 cells. ALCAN was also secreted from these cells, suggesting
that some portion of the molecules was secreted by enzymatic cleavage by,
for example, phospholipases. Mutational analysis of ALCAN suggested that th
e GPI-anchored position was the Ser(216) residue. These findings indicate t
hat ALCAN may be a potential target for cancer diagnosis or therapy, (C) 20
01 Academic Press.